^
Original-Research: Aiforia Technologies Oyj - from NuWays AG
23.10.2025 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.
---------------------------------------------------------------------------
Classification of NuWays AG to Aiforia Technologies Oyj
Company Name: Aiforia Technologies Oyj
ISIN: FI4000507934
Reason for the research: Initiation
Recommendation: BUY
from: 23.10.2025
Target price: EUR 3.50
Target price on sight of: 12 months
Last rating change:
Analyst: Julius Neittamo
Disrupting the pathology playbook with AI; INITIATE with BUY
The supply-demand dynamics in cancer diagnostics are increasingly
imbalanced. While the number of new cancer cases is projected to rise by 50%
until 2040, the number of pathologists continues to decline. Bridging this
gap requires the digitalisation of pathology workflows and the adoption of
artificial intelligence (AI); enabling faster, more accurate diagnoses and
ultimately improving patient outcomes.
Aiforia sits at the forefront of this transformation. The company has
developed a leading AI-powered image analysis platform that automates key
tasks within the pathology workflow, helping laboratories and hospitals
dramatically increase efficiency and diagnostic accuracy. For instance, a
research study evaluated how well Aiforia's AI fared against pathologists,
in measuring cell growth in gastrointestinal neuroendocrine tumors. This
study found that Aiforia's AI model outperformed pathologists in both
accuracy and reliability.
Market leadership for a reason. Aiforia has won 100% of the European
clinical tenders it has entered (>30% market share), reflecting its
exceptional competitive quality. Its platform currently covers 60% of known
cancer types (target of >80% within the next few years), with half of its
models already holding regulatory approval, more than any other competitor.
Aiforia's AI delivers granular, cellular-level insights, enabling more
precise and reliable diagnoses. With a strong research pedigree, including
collaborations with leading universities, Aiforia is consistently the
solution of choice in academic studies and published research.
Digital pathology is reaching a critical inflection point, with global
adoption for disease diagnosis set to accelerate from 22% in 2024 to 50% by
2029. This rapid market transformation, combined with Aiforia's unique
positioning, underpins the company's ability to outpace the broader
pathology AI market, which is expected to grow at 21% CAGR, while Aiforia is
projected to achieve a 52% CAGR (FY29e EUR 23m sales, eNuW) over the same
period. This growth is driven by both an increasing customer base and a
sharp rise in the number of slides processed for existing clients.
Leveraging a capital-light, software-based model, the company offers
excellent scalability with minimal client churn in a maturing market. Like
other leading healthcare technology firms, Aiforia is expected to deliver
strong operating leverage, converting top-line growth into sustainable
profitability, with EBIT margins projected at 27-32% at maturity (eNuW).
We see Aiforia as a structural growth story with a clear pathway to scale
and profitability. Its technology directly addresses one of healthcare's
most pressing challenges, the diagnostic capacity gap, while offering
investors exposure to the broader theme of AI-enabled medical automation. We
initiate coverage with a BUY rating and a EUR 3.50 price target based on our
DCF valuation.
You can download the research here:
https://eqs-cockpit.com/c/fncls.ssp?u=85236f4783db5b29d6d3c59256e1e051
For additional information visit our website:
https://www.nuways-ag.com/research-feed
Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
---------------------------------------------------------------------------
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=e67e30bc-afd7-11f0-be29-0694d9af22cf&lang=en
---------------------------------------------------------------------------
2217314 23.10.2025 CET/CEST
°